Sildenafil Administration to Treat Neonatal Encephalopathy

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 18% of the time (141 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-01-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: injuryhoursbirthneonatalrepair
  Phrases that lowered it: treatmenttreatedtherapyof lifecontinued
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 12.3% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Drug's FAERS reports marked serious: 64.9% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 16.3% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 38 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Disease area, neurology: Yes (raises risk) · Disease area
• Minimum age: not given (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports before start: 56909 (lowers risk) · Drug's FDA history
• Collaborators: 0 (raises risk) · Design
• Keywords listed: 8 (lowers risk) · Design
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Sildenafil to Repair Brain Injury Secondary to Birth Asphyxia NCT04169191 · started 2019 · scored riskier than 63% of active trials completed
• Safety and Efficacy of Topiramate in Neonates With Hypoxic Ischemic Encephalopathy Treated With Hypothermia NCT01241019 · started 2010 · scored riskier than 56% of active trials completed
• Finding Solutions to Thrive After Birth Asphyxia in Africa NCT05275725 · started 2022 · scored riskier than 29% of active trials completed
• Melatonin for Neuroprotection Following Perinatal Asphyxia NCT02071160 · started 2012 · scored riskier than 6% of active trials completed
• Hydrocortisone Treatment In Systemic Low Blood Pressure During Hypothermia in Asphyxiated Newborns NCT02700828 · started 2016 · scored riskier than 49% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.